Davita Inc Intrinsic Stock Value – DaVita Stock Falls Behind Competitors on Friday
December 28, 2023
🌥️Trending News
DAVITA ($NYSE:DVA): On Friday, DaVita Inc.’s stock did not perform as well as its competitors. DaVita Inc. is an American healthcare company specializing in kidney care. The company’s stock has been under pressure for a while, and Friday was no exception. Despite the company’s strong financials, its stock fell behind its competitors on the day.
Analysts have attributed this to macroeconomic factors, as well as investor sentiment regarding the company. Despite the market’s reaction on Friday, DaVita Inc. remains one of the top companies in its field and looks to have a bright future ahead.
Share Price
On Friday, DaVita Inc. stock took a dip compared to their competitors, as the opening price of $104.1 dropped to a closing price of $104.5, only up 0.2% from the previous closing price of 104.3. This dip comes as a surprise given the company’s usually strong stock performance, and could indicate a downward trend for DaVita Inc stocks in the near future. However, the long-term view of the company still appears to be positive, as investors remain confident in DaVita’s well-established position in the market. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Davita Inc. More…
| Total Revenues | Net Income | Net Margin |
| 11.91k | 608.97 | 5.1% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Davita Inc. More…
| Operations | Investing | Financing |
| 1.92k | -816.77 | -998.15 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Davita Inc. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 16.93k | 14.1k | 13.13 |
Key Ratios Snapshot
Some of the financial key ratios for Davita Inc are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 1.0% | -6.4% | 12.1% |
| FCF Margin | ROE | ROA |
| 11.0% | 81.1% | 5.3% |
Analysis – Davita Inc Intrinsic Stock Value
At GoodWhale, we have conducted a comprehensive analysis of DAVITA INC‘s fundamentals. Our proprietary Valuation Line indicates that the fair value of DAVITA INC share is around $109.1. This presents a great opportunity for investors to purchase DAVITA INC shares on the stock market at a discounted price compared to its fair value. More…
Peers
In the dialysis industry, DaVita Inc. competes with Acadia Healthcare Co Inc, Fresenius Medical Care AG & Co. KGaA, Medical Facilities Corp, and other companies. The company has a network of 2,664 outpatient dialysis centers in the United States that serve approximately 198,000 patients with end-stage renal disease.
– Acadia Healthcare Co Inc ($NASDAQ:ACHC)
Acadia Healthcare Company, Inc. is a provider of behavioral healthcare services. It operates a network of behavioral healthcare facilities in the United States, Puerto Rico, and the United Kingdom. The company offers inpatient psychiatric and substance abuse services, residential treatment, outpatient behavioral health services, and specialty behavioral healthcare services.
– Fresenius Medical Care AG & Co. KGaA ($LTS:0H9X)
Fresenius Medical Care AG & Co. KGaA, a renal care company, provides products and services for patients with renal diseases worldwide. The company’s products and services include dialysis machines, dialyzers, and related disposable products, as well as renal pharmaceuticals. It also offers clinical laboratory testing services. The company was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.
– Medical Facilities Corp ($TSX:DR)
Medical Facilities Corporation is a leading operator of specialty surgical hospitals and ancillary services in the United States. The company owns and operates seven specialty surgical hospitals, one surgical hospital, and three surgical facilities located in Arkansas, Illinois, Louisiana, Mississippi, Oklahoma, and Texas. Medical Facilities Corporation’s hospitals offer a broad range of services, including general surgery, cardiovascular surgery, orthopedic surgery, pain management, gastroenterology, urology, and otolaryngology. The company’s hospitals are accredited by the Joint Commission on Accreditation of Healthcare Organizations and are licensed by the respective state Departments of Health.
Summary
Investors considering DaVita Inc. (NYSE: DVA) should take note of its stock performance on Friday. Analysts are encouraged to review recent earnings reports and financial statements to get a better understanding of the company’s operations and to assess its potential earnings growth. For those looking for short-term returns, it may be prudent to wait for more positive news or sentiment surrounding the stock before investing.
However, for those looking for long-term investments, DaVita Inc. still offers a number of attractive opportunities. Investors should review the company’s competitive position, products, services, customer base, and management team in order to properly evaluate the company’s potential return on investment.
